MEHANDAR KUMAR: Open Payments
NPI 1790082550 · KEANSBURG, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$659 in 30 payments from 17 companies in 2025. Trend: 2023 $995 · 2024 $978 · 2025 $659
Food & beverage: $659
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 4 | $172 |
| Janssen Biotech, Inc. | 5 | $84 |
| Eisai Inc. | 3 | $60 |
| GlaxoSmithKline, LLC. | 3 | $58 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| TAIHO ONCOLOGY, INC. | 2 | $31 |
| ABBVIE INC. | 1 | $30 |
| Aveo Pharmaceuticals, Inc. | 1 | $23 |
| Novartis Pharmaceuticals Corporation | 1 | $23 |
| Genentech USA, Inc. | 1 | $21 |
Products named: OPDIVO, Lenvima, VENCLEXTA, OJJAARA, ERLEADA, LONSURF, FOTIVDA, Fabhalta.
Industry payments across NJ — which companies pay providers there.
